As Founder and CEO of AlleyCorp, Kevin Ryan co-founded MongoDB, Nomad Health, Business Insider, Gilt Groupe, and Zola. AlleyCorp recently launched the $100M AlleyCorp Healthcare Fund dedicated to investing in early-stage healthcare companies in New York City.‍ Earlier in his career, Kevin helped to grow DoubleClick first as President and then as CEO, leading their growth from a 20-person startup to a publicly traded global leader with over 1,500 employees, through IPO in 1998 and acquisition by Google in 2007. Kevin serves on the board of Mercy Corps, is Vice Chairman of The Partnership for New York City, is a member of the CFR Committee on Foreign Affairs, is on the Board of TECH:NYC and is Director Emeritus for Human Rights Watch. He previously served on the boards of the Yale Corporation, INSEAD, the Direct Marketing Association, The Ad Council, HotJobs and the advisory board of Doctors Without Borders. He holds a B.A. from Yale University and an M.B.A. from INSEAD.

Blake previously led the frontier technology practice at AlleyCorp, where he helped incubate two companies in 2020 that have since raised >$20M in venture capital. He co-wrote the Psychedelic Science Funders Collaborative’s Landscape Report and was a founding advisor to the PSFC Investment Circle.‍

Ben is the Co-Director of the Yale Program for Psychedelic Science and an Assistant Professor of Psychiatry at the Yale School of Medicine, one of the top-ranked psychiatry programs worldwide. He was the Principal Investigator on the first double-blind clinical trial investigating psilocybin in the treatment of OCD, and demonstrated early efficacy for esketamine. In 2021, Ben was the first recipient of a federal grant for clinical psychedelic research since 1967.‍

Marty was previously Chief Development Officer and Director at Oncoceutics, which was acquired by Chimerix in Q1 2021. He brings 39 years of senior executive experience in the pharmaceutical industry, and has led research and development resulting in FDA approval of nine New Drug Applications, issuance of 39 US patents, and five major biopharma exits for $3.5B in combined value.

Amanda joins from Axsome Therapeutics, where she led the clinical development of the first and only oral NMDA receptor antagonist approved for treating major depressive disorder in adults (Auvelity®). Prior to joining Axsome, she had varying roles of increasing responsibility in clinical research & development at Salix Pharmaceuticals and United Therapeutics. Amanda earned her Doctor of Pharmacy degree and completed a post-doctoral fellowship in clinical research and drug development at UNC-Chapel Hill Eshelman School of Pharmacy. She earned her B.S. in Biochemistry from Florida State University.

Megan previously worked as a Life Sciences consultant at Charles River Associates, focusing on commercial strategy for her clients across the pharmaceutical and biotechnology space. She pursued her early passion for mental health and psychopharmacology through the Cognitive Neuroscience program at The University of Pennsylvania.

Jennifer brings over 25 years of neuroscience research experience from MIT (B.S.), Yale (Ph.D.) and the Rockefeller University (post-doctoral fellowship), where she worked closely with Ron Duman - who proposed the neurotrophic hypothesis of antidepressant activity- and Nobel Laureate Paul Greengard, studying neuropsychiatric diseases at molecular, cellular and behavioral levels. Prior to joining Transcend, Jennifer was the Director of R&D at Magnolia Neurosciences.

Sarah completed her PhD in Behavioral Neuroscience at the University of South Carolina under an interdisciplinary T32 grant. She was also a post-doctoral T32 awardee at the Johns Hopkins University, where she demonstrated that sleep fragmentation results in neuroinflammation independent of disease. After her postdoctoral work, she worked as a Principal Scientist at Longevity Biotech where she investigated the contribution of the adaptive immune system on neurodegenerative diseases and the efficacy of a novel peptide drug. Her career has focused on the effects of neuroinflammation on development and its contribution to neurological disease. Both her technical and analytical expertise, in addition to her grantsmanship, have contributed to more than $10 million in grant funding over the course of her career.

Stephanie comes to Transcend from Axsome Therapeutics. In her previous role, Stephanie worked on clinical trials for Major Depressive Disorder, Migraine, ADHD, and Narcolepsy. Studying neuroscience at the University of Vermont catalyzed her interest in neuropsychiatric disease and the pharmaceutical industry.